CME/CE

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

This activity examines the evolving role of ON-state RAS inhibitors in the treatment of non–small cell lung cancer and pancreatic cancer. Experts discuss differences between OFF-state and ON-state RAS inhibition, review early efficacy and safety data from agents such as daraxonrasib, elironrasib, and zoldonrasib, and highlight ongoing clinical trials. The activity also addresses practical considerations for molecular testing, treatment selection, adverse event management, and clinical integration strategies.

This video series focuses on translating multimodality imaging into practical care for patients with hypertrophic cardiomyopathy (HCM). Expert faculty review echocardiography, cardiac magnetic resonance, and emerging imaging strategies to support diagnosis, guide HCM-specific therapies, including the use of cardiac myosin inhibitors, and monitor treatment response. Case-based discussions highlight imaging patterns that inform prognosis and optimize patient outcomes.

This online educational activity highlights cutting-edge clinical trial data shaping the future of care in both locally advanced and recurrent/metastatic HNSCC. Experts review novel approaches such as perioperative immunotherapy, radioenhancers in the definitive setting, and next-generation targeted therapies including bispecific antibodies in advanced disease. Faculty compare toxicity profiles across these strategies, emphasizing practical approaches to early adverse event recognition, prevention, and management. With a focus on real-world implementation, the program equips clinicians to translate investigational findings into informed treatment decisions and safer patient care.

This expert lecture offers a focused review of the expanding role of bispecific antibodies earlier in the disease course of multiple myeloma. Learn about pivotal trial data with unprecedented efficacy that support this shift to use in early-line settings. Safety considerations, including infection risk and mitigation strategies, are addressed to guide real-world implementation. Together, these insights help clinicians optimize patient outcomes as bispecific antibodies move toward earlier integration in multiple myeloma care.

On March 5, 2026, the FDA approved teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

Join Drs. Richard Pratley, David Cherney, and Hiddo Heerspink in this extended panel discussion, focused on results of the FINE-ONE clinical trial, which evaluated finerenone—a nonsteroidal mineralocorticoid receptor antagonist—in participants with type 1 diabetes and CKD. The dynamic conversation, which includes patient vignettes regarding the potential treatment implications, highlights the 25% albuminuria reduction demonstrated in FINE-ONE. Faculty underscores the use of albuminuria as a surrogate endpoint, and call for broader access and implementation of therapies shown to offer renal protection so that no patient is left behind when it comes to treatment for CKD.

This online educational activity, derived from a live Grand Rounds event, focuses on the application of molecular testing, evidence-based therapy selection, and interdisciplinary collaboration in the management of high-risk early-stage breast cancer (EBC) with germline BRCA mutations. In this chapterized activity, Dr. Jane Meisel reviews practical approaches for implementing guideline-directed BRCA testing and highlights disparities that impact equitable access to precision oncology. She also discusses the latest clinical evidence on adjuvant therapy for patients with high-risk EBC with germline BRCA mutations and uses a case-based learning lab to explore individualized adjuvant treatment strategies for these patients. The program also emphasizes proactive management of treatment-related adverse events, including patient counseling and coordinated supportive care, to optimize safety and adherence. Participants will gain practical strategies for integrating germline BRCA mutational status into treatment planning and for strengthening multidisciplinary care pathways, all in service of improving outcomes and reducing disparities for patients with high-risk EBC.

On-demand webcast of expert faculty presentation on the diagnosis and management of obesity for pediatric patients, including communication and patient-centered care strategies to improve health outcomes.

Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for ILD, PAH, and renal crisis, and apply risk stratification strategies to guide earlier intervention. Check out the evolving evidence on treatment selection and serious complications, emphasizing multidisciplinary care models and the role of patient-reported outcomes.